Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
36
AGIO Quote, Financials, Valuation and Earnings
Last price:
$30.24
Seasonality move
:
0.15%
Day range:
$29.01 - $30.52
52-week range:
$22.24 - $46.00
Dividend yield:
0%
P/E ratio:
3.91x
P/S ratio:
32.43x
P/B ratio:
1.48x
Volume:
764.6K
Avg. volume:
886.8K
1-year change:
-11.97%
Market cap:
$1.8B
Revenue:
$54M
EPS (TTM):
-$7.12
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AGIO
Agios Pharmaceuticals, Inc.
|
$12.1M | -$1.95 | 59.92% | -15.51% | $38.88 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 89.86% | -58.59% | $457.00 |
|
CRMD
CorMedix, Inc.
|
$127M | $0.81 | 178.58% | 96.01% | $14.86 |
|
ENTA
Enanta Pharmaceuticals, Inc.
|
$15.3M | -$0.88 | 8.89% | -46.95% | $20.25 |
|
GILD
Gilead Sciences, Inc.
|
$7.7B | $1.83 | 4.27% | 82.18% | $156.59 |
|
KPTI
Karyopharm Therapeutics, Inc.
|
$33.2M | -$2.00 | 5.68% | -61.73% | $15.33 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AGIO
Agios Pharmaceuticals, Inc.
|
$30.23 | $38.88 | $1.8B | 3.91x | $0.00 | 0% | 32.43x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$332.92 | $457.00 | $44.2B | 147.50x | $0.00 | 0% | 11.97x |
|
CRMD
CorMedix, Inc.
|
$7.13 | $14.86 | $561.8M | 3.47x | $0.00 | 0% | 2.40x |
|
ENTA
Enanta Pharmaceuticals, Inc.
|
$14.30 | $20.25 | $415M | -- | $0.00 | 0% | 4.96x |
|
GILD
Gilead Sciences, Inc.
|
$148.95 | $156.59 | $184.9B | 21.96x | $0.79 | 2.12% | 6.35x |
|
KPTI
Karyopharm Therapeutics, Inc.
|
$9.41 | $15.33 | $172.6M | -- | $0.00 | 0% | 0.70x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AGIO
Agios Pharmaceuticals, Inc.
|
3.26% | 2.234 | 2.53% | 10.52x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 1.064 | 5.64% | 2.51x |
|
CRMD
CorMedix, Inc.
|
1.16% | 2.679 | 0.48% | 1.60x |
|
ENTA
Enanta Pharmaceuticals, Inc.
|
60.41% | 1.706 | 42.21% | 4.35x |
|
GILD
Gilead Sciences, Inc.
|
52.94% | 0.008 | 16.78% | 1.23x |
|
KPTI
Karyopharm Therapeutics, Inc.
|
-393.82% | 0.475 | 173.34% | 0.98x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AGIO
Agios Pharmaceuticals, Inc.
|
$16.8M | -$121.6M | -29.08% | -30.11% | -608.9% | -$97.3M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
ENTA
Enanta Pharmaceuticals, Inc.
|
$17.4M | -$11.3M | -23.61% | -75.15% | -60.45% | -$11.8M |
|
GILD
Gilead Sciences, Inc.
|
$6.3B | $3B | 18.53% | 41.72% | 37.64% | $3.1B |
|
KPTI
Karyopharm Therapeutics, Inc.
|
$32.6M | -$17.8M | -1579.24% | -- | -52.36% | -$11.8M |
Agios Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns AGIO or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -541.09% compared to Agios Pharmaceuticals, Inc.'s net margin of 16.99%. Agios Pharmaceuticals, Inc.'s return on equity of -30.11% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital AGIOAgios Pharmaceuticals, Inc.84.25% -$1.85 $1.2B ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About AGIO or ALNY?
Agios Pharmaceuticals, Inc. has a consensus price target of $38.88, signalling upside risk potential of 28.6%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 37.27%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than Agios Pharmaceuticals, Inc., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than Agios Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AGIOAgios Pharmaceuticals, Inc.7 3 0 ALNYAlnylam Pharmaceuticals, Inc.15 7 0 -
Is AGIO or ALNY More Risky?
Agios Pharmaceuticals, Inc. has a beta of 0.915, which suggesting that the stock is 8.508% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.
-
Which is a Better Dividend Stock AGIO or ALNY?
Agios Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agios Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AGIO or ALNY?
Agios Pharmaceuticals, Inc. quarterly revenues are $20M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Agios Pharmaceuticals, Inc.'s net income of -$108M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Agios Pharmaceuticals, Inc.'s price-to-earnings ratio is 3.91x while Alnylam Pharmaceuticals, Inc.'s PE ratio is 147.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals, Inc. is 32.43x versus 11.97x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AGIOAgios Pharmaceuticals, Inc.32.43x 3.91x $20M -$108M ALNYAlnylam Pharmaceuticals, Inc.11.97x 147.50x $1.1B $186.4M
-
Which has Higher Returns AGIO or CRMD?
CorMedix, Inc. has a net margin of -541.09% compared to Agios Pharmaceuticals, Inc.'s net margin of 49.9%. Agios Pharmaceuticals, Inc.'s return on equity of -30.11% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital AGIOAgios Pharmaceuticals, Inc.84.25% -$1.85 $1.2B CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About AGIO or CRMD?
Agios Pharmaceuticals, Inc. has a consensus price target of $38.88, signalling upside risk potential of 28.6%. On the other hand CorMedix, Inc. has an analysts' consensus of $14.86 which suggests that it could grow by 108.38%. Given that CorMedix, Inc. has higher upside potential than Agios Pharmaceuticals, Inc., analysts believe CorMedix, Inc. is more attractive than Agios Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AGIOAgios Pharmaceuticals, Inc.7 3 0 CRMDCorMedix, Inc.4 0 0 -
Is AGIO or CRMD More Risky?
Agios Pharmaceuticals, Inc. has a beta of 0.915, which suggesting that the stock is 8.508% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.388, suggesting its more volatile than the S&P 500 by 38.76%.
-
Which is a Better Dividend Stock AGIO or CRMD?
Agios Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agios Pharmaceuticals, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AGIO or CRMD?
Agios Pharmaceuticals, Inc. quarterly revenues are $20M, which are smaller than CorMedix, Inc. quarterly revenues of $104.3M. Agios Pharmaceuticals, Inc.'s net income of -$108M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Agios Pharmaceuticals, Inc.'s price-to-earnings ratio is 3.91x while CorMedix, Inc.'s PE ratio is 3.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals, Inc. is 32.43x versus 2.40x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AGIOAgios Pharmaceuticals, Inc.32.43x 3.91x $20M -$108M CRMDCorMedix, Inc.2.40x 3.47x $104.3M $108.6M
-
Which has Higher Returns AGIO or ENTA?
Enanta Pharmaceuticals, Inc. has a net margin of -541.09% compared to Agios Pharmaceuticals, Inc.'s net margin of -64.13%. Agios Pharmaceuticals, Inc.'s return on equity of -30.11% beat Enanta Pharmaceuticals, Inc.'s return on equity of -75.15%.
Company Gross Margin Earnings Per Share Invested Capital AGIOAgios Pharmaceuticals, Inc.84.25% -$1.85 $1.2B ENTAEnanta Pharmaceuticals, Inc.93.39% -$0.42 $319.8M -
What do Analysts Say About AGIO or ENTA?
Agios Pharmaceuticals, Inc. has a consensus price target of $38.88, signalling upside risk potential of 28.6%. On the other hand Enanta Pharmaceuticals, Inc. has an analysts' consensus of $20.25 which suggests that it could grow by 41.61%. Given that Enanta Pharmaceuticals, Inc. has higher upside potential than Agios Pharmaceuticals, Inc., analysts believe Enanta Pharmaceuticals, Inc. is more attractive than Agios Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AGIOAgios Pharmaceuticals, Inc.7 3 0 ENTAEnanta Pharmaceuticals, Inc.4 1 0 -
Is AGIO or ENTA More Risky?
Agios Pharmaceuticals, Inc. has a beta of 0.915, which suggesting that the stock is 8.508% less volatile than S&P 500. In comparison Enanta Pharmaceuticals, Inc. has a beta of 0.982, suggesting its less volatile than the S&P 500 by 1.803%.
-
Which is a Better Dividend Stock AGIO or ENTA?
Agios Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Enanta Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agios Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Enanta Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AGIO or ENTA?
Agios Pharmaceuticals, Inc. quarterly revenues are $20M, which are larger than Enanta Pharmaceuticals, Inc. quarterly revenues of $18.6M. Agios Pharmaceuticals, Inc.'s net income of -$108M is lower than Enanta Pharmaceuticals, Inc.'s net income of -$11.9M. Notably, Agios Pharmaceuticals, Inc.'s price-to-earnings ratio is 3.91x while Enanta Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals, Inc. is 32.43x versus 4.96x for Enanta Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AGIOAgios Pharmaceuticals, Inc.32.43x 3.91x $20M -$108M ENTAEnanta Pharmaceuticals, Inc.4.96x -- $18.6M -$11.9M
-
Which has Higher Returns AGIO or GILD?
Gilead Sciences, Inc. has a net margin of -541.09% compared to Agios Pharmaceuticals, Inc.'s net margin of 27.44%. Agios Pharmaceuticals, Inc.'s return on equity of -30.11% beat Gilead Sciences, Inc.'s return on equity of 41.72%.
Company Gross Margin Earnings Per Share Invested Capital AGIOAgios Pharmaceuticals, Inc.84.25% -$1.85 $1.2B GILDGilead Sciences, Inc.79.65% $1.74 $48.2B -
What do Analysts Say About AGIO or GILD?
Agios Pharmaceuticals, Inc. has a consensus price target of $38.88, signalling upside risk potential of 28.6%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $156.59 which suggests that it could grow by 5.13%. Given that Agios Pharmaceuticals, Inc. has higher upside potential than Gilead Sciences, Inc., analysts believe Agios Pharmaceuticals, Inc. is more attractive than Gilead Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AGIOAgios Pharmaceuticals, Inc.7 3 0 GILDGilead Sciences, Inc.17 7 0 -
Is AGIO or GILD More Risky?
Agios Pharmaceuticals, Inc. has a beta of 0.915, which suggesting that the stock is 8.508% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.360, suggesting its less volatile than the S&P 500 by 63.985%.
-
Which is a Better Dividend Stock AGIO or GILD?
Agios Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences, Inc. offers a yield of 2.12% to investors and pays a quarterly dividend of $0.79 per share. Agios Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Gilead Sciences, Inc. pays out 46.6% of its earnings as a dividend. Gilead Sciences, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AGIO or GILD?
Agios Pharmaceuticals, Inc. quarterly revenues are $20M, which are smaller than Gilead Sciences, Inc. quarterly revenues of $8B. Agios Pharmaceuticals, Inc.'s net income of -$108M is lower than Gilead Sciences, Inc.'s net income of $2.2B. Notably, Agios Pharmaceuticals, Inc.'s price-to-earnings ratio is 3.91x while Gilead Sciences, Inc.'s PE ratio is 21.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals, Inc. is 32.43x versus 6.35x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AGIOAgios Pharmaceuticals, Inc.32.43x 3.91x $20M -$108M GILDGilead Sciences, Inc.6.35x 21.96x $8B $2.2B
-
Which has Higher Returns AGIO or KPTI?
Karyopharm Therapeutics, Inc. has a net margin of -541.09% compared to Agios Pharmaceuticals, Inc.'s net margin of -299.89%. Agios Pharmaceuticals, Inc.'s return on equity of -30.11% beat Karyopharm Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AGIOAgios Pharmaceuticals, Inc.84.25% -$1.85 $1.2B KPTIKaryopharm Therapeutics, Inc.95.59% -$5.71 -$59.3M -
What do Analysts Say About AGIO or KPTI?
Agios Pharmaceuticals, Inc. has a consensus price target of $38.88, signalling upside risk potential of 28.6%. On the other hand Karyopharm Therapeutics, Inc. has an analysts' consensus of $15.33 which suggests that it could grow by 62.95%. Given that Karyopharm Therapeutics, Inc. has higher upside potential than Agios Pharmaceuticals, Inc., analysts believe Karyopharm Therapeutics, Inc. is more attractive than Agios Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AGIOAgios Pharmaceuticals, Inc.7 3 0 KPTIKaryopharm Therapeutics, Inc.4 1 0 -
Is AGIO or KPTI More Risky?
Agios Pharmaceuticals, Inc. has a beta of 0.915, which suggesting that the stock is 8.508% less volatile than S&P 500. In comparison Karyopharm Therapeutics, Inc. has a beta of 0.208, suggesting its less volatile than the S&P 500 by 79.163%.
-
Which is a Better Dividend Stock AGIO or KPTI?
Agios Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Karyopharm Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agios Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Karyopharm Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AGIO or KPTI?
Agios Pharmaceuticals, Inc. quarterly revenues are $20M, which are smaller than Karyopharm Therapeutics, Inc. quarterly revenues of $34.1M. Agios Pharmaceuticals, Inc.'s net income of -$108M is lower than Karyopharm Therapeutics, Inc.'s net income of -$102.2M. Notably, Agios Pharmaceuticals, Inc.'s price-to-earnings ratio is 3.91x while Karyopharm Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals, Inc. is 32.43x versus 0.70x for Karyopharm Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AGIOAgios Pharmaceuticals, Inc.32.43x 3.91x $20M -$108M KPTIKaryopharm Therapeutics, Inc.0.70x -- $34.1M -$102.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
54
AAOI alert for Feb 28
Applied Optoelectronics, Inc. [AAOI] is up 56.96% over the past day.
Buy
90
BNAI alert for Feb 28
Brand Engagement Network, Inc. [BNAI] is up 36.02% over the past day.
Sell
36
WLDN alert for Feb 28
Willdan Group, Inc. [WLDN] is down 25.56% over the past day.
